InSilico Medicine Cayman (HKG: 03696)

• ·InSilico Medicine Cayman (HKG: 03696)’s last known valuation is $1.7B (Dec 2025).
• ·It has raised $841.9M across 6 recorded rounds; the latest was Early Stage VC ($13.0M) in Jun 2025.
• ·Notable investors include Hongshan Capital Group, F-Prime Capital, Qiming Venture Partners, Eight Roads, Aramco Ventures — 50 tracked in total.
• ·Status: Publicly Held.

InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from Hong Kong.

Industry

Biotech

Sector

Healthcare

HQ

Hong Kong, MA, Hong Kong

Founded

2014

Employees

317

Website

insilico.com/

Ownership

Publicly Held